Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Official title:
A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
| Verified date | September 2020 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR
| Status | Completed |
| Enrollment | 112 |
| Est. completion date | July 6, 2020 |
| Est. primary completion date | September 26, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 130 Years |
| Eligibility |
Inclusion Criteria: - Age =18 years - Written informed consent obtained from the patient/legal representative - Histologically confirmed recurrent or metastatic SCCHN - Tumor progression or recurrence during or after treatment with only 1 systemic palliative regimen for recurrent or metastatic disease that must have contained a platinum agent. - Written consent to provide newly acquired tumor tissue (preferred) or archival tissue for the purpose of establishing PD-L1 status. - Confirmed PD-L1-positive SCCHN by Ventana SP263 assay - WHO/ECOG performance status of 0 or 1 - At least 1 measurable lesion at baseline - No prior exposure to immune-mediated therapy - Adequate organ and marrow function - Evidence of post-menopausal status or negative urinary or serum pregnancy test. Exclusion Criteria: - Histologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck - Received more than 1 systematic palliative regimen for recurrent or metastatic disease - Any concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer treatment - Prior randomization or treatment in a previous MEDI4736 and/or tremelimumab clinical study regardless of treatment arm assignment or receipt of any investigational anticancer therapy within 28 days or 5 half-lives - Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment - Major surgical procedure within 28 days prior to the first dose of Investigational Product - Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion - Current or prior use of immunosuppressive medication within 14 days before the first dose of MEDI4736 - History of allogeneic organ transplantation - Active or prior documented autoimmune or inflammatory disorders; - Uncontrolled intercurrent illness - Another primary malignancy - Patients with history of brain metastases, spinal cord compression, or leptomeningeal carcinomatosis - History of active primary immunodeficiency - Known history of previous tuberculosis - Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV) - Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736 - Pregnant or breast-feeding female patients - Mean QT interval corrected for heart rate (QTc) =470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's Correction - Any condition that, in the opinion of the Investigator, would interfere with evaluation of the IP or interpretation of patient safety or study results |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | Research Site | Brussels | |
| Belgium | Research Site | Kortrijk | |
| Belgium | Research Site | Leuven | |
| Belgium | Research Site | Montigny-le-Tilleul | |
| Belgium | Research Site | Namur | |
| Canada | Research Site | Calgary | Alberta |
| Canada | Research Site | London | Ontario |
| Canada | Research Site | Montreal | Quebec |
| Canada | Research Site | Ottawa | Ontario |
| Canada | Research Site | Toronto | Ontario |
| Czechia | Research Site | Zlin | |
| France | Research Site | Angers | |
| France | Research Site | Bordeaux | |
| France | Research Site | Brest | |
| France | Research Site | Clermont Ferrand | |
| France | Research Site | Dijon | |
| France | Research Site | Le Mans | |
| France | Research Site | Lille cedex | |
| France | Research Site | Lorient cedex | |
| France | Research Site | Lyon Cedex 08 | |
| France | Research Site | Montpellier Cedex 05 | |
| France | Research Site | Nice | |
| France | Research Site | Plerin SUR MER | |
| France | Research Site | Rouen | |
| France | Research Site | St Grégoire | |
| France | Research Site | Strasbourg Cedex | |
| France | Research Site | Toulouse Cedex 9 | |
| France | Research Site | Villejuif Cedex | |
| Georgia | Research Site | Batumi | |
| Georgia | Research Site | Tbilisi | |
| Georgia | Research Site | Tbilisi | |
| Georgia | Research Site | Tbilisi | |
| Germany | Research Site | Berlin | |
| Germany | Research Site | Halle | |
| Germany | Research Site | Heidelberg | |
| Germany | Research Site | Leipzig | |
| Germany | Research Site | München | |
| Hungary | Research Site | Budapest | |
| Hungary | Research Site | Budapest | |
| Hungary | Research Site | Gyula | |
| Israel | Research Site | Haifa | |
| Israel | Research Site | Petach-Tikva | |
| Israel | Research Site | Tel Hashomer | |
| Korea, Republic of | Research Site | Daegu | |
| Korea, Republic of | Research Site | Goyang-si | |
| Korea, Republic of | Research Site | Seoul | |
| Korea, Republic of | Research Site | Suwon | |
| Malaysia | Research Site | Kuala Lumpur | |
| Malaysia | Research Site | Kuching | |
| Malaysia | Research Site | Sabah | |
| Spain | Research Site | Barakaldo | |
| Spain | Research Site | Barcelona | |
| Spain | Research Site | Barcelona | |
| Spain | Research Site | Barcelona | |
| Spain | Research Site | L'Hospitalet de Llobregat | |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Malaga | |
| Spain | Research Site | Marbella (Málaga) | |
| Spain | Research Site | Pamplona | |
| Spain | Research Site | Valencia | |
| Spain | Research Site | Valencia | |
| Spain | Research Site | Zaragoza | |
| Taiwan | Research Site | Taipei | |
| United Kingdom | Research Site | Birmingham | |
| United Kingdom | Research Site | Glasgow | |
| United Kingdom | Research Site | London | |
| United Kingdom | Research Site | Manchester | |
| United Kingdom | Research Site | Wirral | |
| United States | Research Site | Ann Arbor | Michigan |
| United States | Research Site | Augusta | Georgia |
| United States | Research Site | Austin | Texas |
| United States | Research Site | Baltimore | Maryland |
| United States | Research Site | Baltimore | Maryland |
| United States | Research Site | Birmingham | Alabama |
| United States | Research Site | Boston | Massachusetts |
| United States | Research Site | Buffalo | New York |
| United States | Research Site | Dallas | Texas |
| United States | Research Site | Denver | Colorado |
| United States | Research Site | Duarte | California |
| United States | Research Site | Durham | North Carolina |
| United States | Research Site | Evanston | Illinois |
| United States | Research Site | Fairfax | Virginia |
| United States | Research Site | Fullerton | California |
| United States | Research Site | Germantown | Tennessee |
| United States | Research Site | Jacksonville | Florida |
| United States | Research Site | Lebanon | New Hampshire |
| United States | Research Site | Lexington | Kentucky |
| United States | Research Site | Long Beach | California |
| United States | Research Site | Los Angeles | California |
| United States | Research Site | Los Angeles | California |
| United States | Research Site | Los Angeles | California |
| United States | Research Site | Macon | Georgia |
| United States | Research Site | Milwaukee | Wisconsin |
| United States | Research Site | Minneapolis | Minnesota |
| United States | Research Site | Morgantown | West Virginia |
| United States | Research Site | Nashville | Tennessee |
| United States | Research Site | New York | New York |
| United States | Research Site | Portland | Oregon |
| United States | Research Site | Rochester | Minnesota |
| United States | Research Site | Saint Louis | Missouri |
| United States | Research Site | San Francisco | California |
| United States | Research Site | Southfield | Michigan |
| United States | Research Site | Stony Brook | New York |
| United States | Research Site | Whittier | California |
| United States | Research Site | Winston-Salem | North Carolina |
| United States | Research Site | Yuma | Arizona |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca | PRA Health Sciences |
United States, Belgium, Canada, Czechia, France, Georgia, Germany, Hungary, Israel, Korea, Republic of, Malaysia, Spain, Taiwan, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Objective response rate (per RECIST 1.1 as assessed by blinded independent central review [BICR]) is defined as the number (%) of patients with a confirmed complete response or confirmed partial response and will be based on all treated patients who are PD-L1-positive with measurable disease at baseline per BICR. Response Evaluation Criteria in Solid Tumors [RECIST] 1.1. criteria are: Complete response [CR] = disappearance of all target lesions since baseline; and partial response [PR] = at least a 30% decrease in the sum of the diameters of target lesions. |
12 months | |
| Secondary | Best Objective Response | Best objective response based on BICR assessments according to RECIST v1.1. Response required confirmation after 4 weeks. Unconfirmed complete (CR) or partial response (PR) refers to CR or PR achieved but either no confirmation assessment was performed or a confirmation assessment was performed but response was not confirmed. |
12 months | |
| Secondary | Duration of Response- Participants Remaining in Response | Participants remaining in response - based on BICR assessments according to RECIST v1.1. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off. |
12 months | |
| Secondary | Duration of Response | Duration of objective response in patients with objective response based on BICR assessments according to RECIST v1.1. Duration of response was the time from the first documentation of complete or partial response until the date of progression (which was subsequently confirmed), death, or the last evaluable RECIST assessment for patients that did not progress. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off. |
12 months | |
| Secondary | Time to Onset of Response From First Dose | Time to onset of response in patients with objective response based on BICR assessments according to RECIST 1.1 | 12 months | |
| Secondary | Disease Control at 6 Months | Disease control (DCR) at 6 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD): Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following the start of study treatment. Method 2: Patients who had a best objective response of CR or PR within 24 weeks or had demonstrated SD for a minimum interval of 16 weeks following the start of study treatment. |
6 months | |
| Secondary | Progression-free Survival | Progression status based on BICR assessments according to RECIST v1.1 at time of PFS analysis. Progression was defined as the time from the date of first dose until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. |
12 months | |
| Secondary | Overall Survival (OS) | Survival status at time of overall survival analysis. 'Still in survival follow-up' includes patients known to be alive at data cut-off. 'Terminated prior to death' includes patients with unknown survival status, or who were lost to follow-up. | 12 months | |
| Secondary | Quality of Life | Improvement in quality of life was assessed using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires: The impact of treatment on Health-Related Quality of Life, functioning, and symptoms was evaluated using the EORTC QLQ-C30 v3. Head and neck cancer-specific symptoms were evaluated using the EORTC QLQ-H&N35. Function or global health status/quality of life improvement was defined as patients with 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (an increase from baseline score =10). Symptom improvement was defined as 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (a decrease from baseline score =10). Scale improvement was defined as patients with 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (a decrease from baseline score =10). |
12 months |